---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-117214"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:59:34.453209+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharma Q3 net loss $2.8M; cash $5.8M; advancing ibezapolstat Phase 3

## Summary
- Net loss $2.8M ($0.17/diluted share) vs $3.1M ($0.24) in Q3 2023; nine-month net loss $11.3M.
- Cash $5.8M at Sep 30, 2024, down from $7.5M at Dec 31, 2023; raised $1.6M gross via ATM.
- Requested FDA CMC meeting to start Phase 3 for ibezapolstat; USPTO patent granted through 2042.
- R&D expenses $1.2M (Q3) vs $1.3M prior year; G&A $1.6M vs $1.8M prior year.

## SEC filing metadata
- accession: 0001104659-24-117214
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465924117214/0001104659-24-117214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465924117214/tm2428175d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-117214
- JSON: https://secwatch.observer/filing/0001104659-24-117214.json
- Plain text: https://secwatch.observer/filing/0001104659-24-117214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.